Real-life Clinical FEIBA Samples Measured Using the Version A of the HemA EnzySystem

Hemophilia A Clinical Trial

Official title:

Real-life Clinical FEIBA Samples Measured Using the Version A of the HemA EnzySystem

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06357572
• Other study ID #: ENZ13-2024
• Status: Completed
• Start date: March 26, 2024
• Est. completion date: March 27, 2024

Study information

• Verified date: April 2024
• Source: Enzyre B.V.
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The goal of this observational study is to assess if the version A of the HemA EnzySystem, a novel portable coagulation testing platform, can be used in patients with hemophilia A treated with Factor VIII Bypassing Agent (FEIBA). The main question[s] it aims to answer are:

• Can the version A of the HemA EnzySystem can record thrombin generation within a time frame of 60 min in fresh whole blood samples of patients with hemophilia A treated with FEIBA?

• Are the TGA results of the version A of the HemA EnzySystem in agreement with the TGA results obtained with conventional methods in fresh non frozen plasma?

Participants are asked to fill in a questionnaire regarding their general health and hemophilia treatment. Subsequently, blood will be drawn from the patients before, and at 30, 120, and 240 minutes after FEIBA administration. Whole blood is immediately tested using the Version A HemA EnzySystem, and plasma is generated for testing with the Ceveron s100 (Technoclone). Leftover samples are frozen for later additional coagulation testing.

Description:

Rationale: Hemophilia is an X-linked hemostatic bleeding disorder characterized by a lack of coagulation factor VIII activity (HemA) or factor IX activity (HemB). Spontaneous major bleeding in joints and muscles frequently occur when factor activity levels are low. Currently, there is a growing evidence that the bleeding phenotype of hemophilia A patients is not only reflected by the actual factor VIII activity level, as there is a large variety in bleeding among patients with similar factor VIII activity.

Currently, patients with severe Hemophilia A are treated with either FVIII containing products or Emicizumab. Initially emicizumab was described for patients who developed inhibitors as inhibitors do not interfere with emicizumab. Despite, bleeding complications still may occur and therefore bypassing therapies are still of great importance. Unfortunately, monitoring treatment with these drugs is a challenge.

Thrombin generation profile may be an additional tool in hemophilia patients to differentiate between bleeding phenotype, to guide prophylactic replacement therapy and adjust bypassing therapy, especially in patients treated with emicizumab. Based on recent studies, thrombin generation as a global hemostasis assay offers an opportunity to assess the hemostatic capacity of patients, and therefore has much potential for monitoring therapy. To facilitate this, a hand-held in vitro diagnostic medical device able to simultaneously measure multiple disease biomarkers with a single drop of blood is currently in development, focusing on simultaneous measurements of Factor VIII activity and Thrombin generation.

Objective: The primary objective of this study is to demonstrate that the version A of the HemA EnzySystem can record thrombin generation within a time frame of 60 min in fresh whole blood samples of patients with hemophilia A treated with Factor VIII Bypassing Agent (FEIBA). As secondary objective, the study results will be validated with a Thrombin Generation Assay (TGA) measured in freshly obtained non frozen plasma.

Study design: This is a cross-sectional observational study. All participants are asked to fill a questionnaire prior to blood collection of four tubes. Blood sample measurements will be conducted within a two-hour time frame using the version A of the HemA EnzySystem and the preparation of plasma using a standard TGA assay. Any remaining blood material will be processed and stored.

Study population: The study population consists of 6 patients treated with FEIBA. In total, at least 24 samples are tested, four for each patient (t=0, 30, 120 and 240 minutes).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6
• Est. completion date: March 27, 2024
• Est. primary completion date: March 27, 2024
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion criteria (all of the following)

• Diagnosed with mild (FVIII activity levels 5-40%), moderate (FVIII activity levels 1-5%) or severe hemophilia A (FVIII activity levels <1%)

• With inhibitors

• On prophylactic or on-demand treatment with FEIBA (variation in dosing and duration of therapy use)

Exclusion Criteria:

• use of anticoagulants or platelet antagonists (aspirin or any TAR);

• known allergy to stainless steel;

• a bleeding episode within the last two weeks;

• clinical indication of liver cirrhosis (ultrasonography indication, enlarged spleen, decreased platelet count <100 G/l);

• Signs of inflammation or infection

• Current use of:

NSAIDs; antimicrobial medication; thyroid inhibitors or SSRI's;

Related Conditions & MeSH terms

• Hemophilia A
• Hemophilia A With Inhibitor

Intervention

Diagnostic Test:
• Thrombin generation assay (EnzySystem HemA version A - whole blood)
Whole blood obtained by venipuncture is immediately tested with the EnzySystem HemA version A), before and 0, 30, 120 and 240 minutes after administration of FEIBA.
• Thrombin generation assay (Ceveron s100 (Technoclone) - fresh plasma)
Whole blood is centrifuged to obtain plasma. The fresh plasma is tested using the Ceveron s100.
• Additional coagulation tests
Plasma samples are frozen for later coagulation testing. The following tests are performed: Factor VIII activity von Willebrand Factor antigen levels von Willebrand Factor ristocetin activity levels Prothrombin Fragment 1+2 levels ADAMTS13 activity FVIII antigen levels Nijmegen Hemostasis Assay

Locations

Country	Name	City	State
Poland	Institute of Hematology and Blood Transfusion	Warsaw	Mazowieckie Województwo

Sponsors (2)

Lead Sponsor	Collaborator
Enzyre B.V.	Instytut Hematologii i Transfuzjologii, Warschau, Poland

Country where clinical trial is conducted

Poland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time between venipuncture and TGA result	The primary objective of this study is to demonstrate that the EnzySystem Thrombin Generation assay can record thrombin generation within a time frame of 60 min. Fresh whole blood samples of patients with hemophilia A on prophylactic or on-demand FEIBA treatment are used and tested in a near-patient setting at the Institute of Hematology and Transfusion Medicine (IHiT)	2 hours
Secondary	Agreement between TGA obtained with the EnzySystem HemA version A and conventional TGA results	Outcome of the TGAlum measured with the version A of the HemA EnzySystem will be compared to the reference TGA which is the standard method of testing at the IHiT to determine patients coagulation status. The reference TGA will be evaluated using the Ceveron by Technoclone	6 hours